$EVFM
Evofem Biosciences, Inc.

2023 Q3 Form 10-Q Financial Statement

#000149315223028671 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $5.112M $2.458M $6.034M
YoY Change -19.76% -59.26% 224.93%
Cost Of Revenue $1.889M $2.293M $1.285M
YoY Change 12.44% 78.44% 53.16%
Gross Profit $3.223M $165.0K $4.749M
YoY Change -31.29% -96.53% 366.5%
Gross Profit Margin 63.05% 6.71% 78.7%
Selling, General & Admin $6.161M $7.099M $21.42M
YoY Change -66.16% -66.86% -36.34%
% of Gross Profit 191.16% 4302.42% 451.13%
Research & Development $614.0K $402.0K $7.744M
YoY Change -88.21% -94.81% -8.97%
% of Gross Profit 19.05% 243.64% 163.07%
Depreciation & Amortization $37.00K $173.0K $250.0K
YoY Change -85.2% -30.8% -7.41%
% of Gross Profit 1.15% 104.85% 5.26%
Operating Expenses $6.775M $7.501M $29.17M
YoY Change -71.07% -74.28% -32.17%
Operating Profit -$3.552M -$7.336M -$24.42M
YoY Change -81.03% -69.96% -40.65%
Interest Expense -$5.173M -$92.00K -$101.1M
YoY Change -104.76% -99.91% -1234.46%
% of Operating Profit
Other Income/Expense, Net $69.57M -$1.219M -$101.5M
YoY Change -35.73% -98.8% -1413.94%
Pretax Income $66.02M -$8.555M -$126.0M
YoY Change -26.25% -93.21% 276.97%
Income Tax $11.00K $3.000K $20.00K
% Of Pretax Income 0.02%
Net Earnings $66.01M -$8.558M -$126.0M
YoY Change -26.26% -93.21% 276.89%
Net Earnings / Revenue 1291.18% -348.17% -2087.84%
Basic Earnings Per Share $15.34 -$5.43 -$4.57
Diluted Earnings Per Share $0.10 -$5.43 -$4.57
COMMON SHARES
Basic Shares Outstanding 4.060M shares 216.0M shares 27.13M shares
Diluted Shares Outstanding 730.0M shares 1.576M shares 27.13M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00 $19.89M
YoY Change -100.0% -100.0% -57.68%
Cash & Equivalents $19.89M
Short-Term Investments
Other Short-Term Assets $2.657M $3.144M $8.772M
YoY Change -56.45% -64.16% -74.75%
Inventory $2.526M $3.674M $6.133M
Prepaid Expenses
Receivables $6.322M $5.198M $7.304M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $11.51M $12.02M $41.91M
YoY Change -63.81% -71.33% -56.18%
LONG-TERM ASSETS
Property, Plant & Equipment $1.631M $1.668M $5.306M
YoY Change -61.86% -68.56% -10.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $35.00K $195.0K $1.224M
YoY Change -96.85% -84.07% 19.88%
Total Long-Term Assets $1.817M $2.058M $11.57M
YoY Change -82.68% -82.21% -11.82%
TOTAL ASSETS
Total Short-Term Assets $11.51M $12.02M $41.91M
Total Long-Term Assets $1.817M $2.058M $11.57M
Total Assets $13.32M $14.07M $53.47M
YoY Change -68.49% -73.68% -50.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.20M $17.15M $15.39M
YoY Change 11.39% 11.46% 99.75%
Accrued Expenses $5.100M $4.216M $6.918M
YoY Change -7.36% -39.06% -7.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $4.054M
YoY Change -100.0%
Long-Term Debt Due $41.08M $43.00M $115.5M
YoY Change -47.01% -62.76% 160.57%
Total Short-Term Liabilities $67.87M $69.72M $265.6M
YoY Change -41.85% -73.75% 288.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $12.43K $22.00K $3.913M
YoY Change -99.44% -25.76%
Total Long-Term Liabilities $12.43K $22.00K $3.913M
YoY Change -99.44% -87.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.87M $69.72M $265.6M
Total Long-Term Liabilities $12.43K $22.00K $3.913M
Total Liabilities $67.88M $69.74M $269.5M
YoY Change -43.59% -74.12% 170.05%
SHAREHOLDERS EQUITY
Retained Earnings -$884.6M -$949.6M -$1.000B
YoY Change -4.92% -5.04% 36.04%
Common Stock $0.00 $0.00 $802.3M
YoY Change -100.0% -100.0% 7.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$56.36M -$55.66M -$216.0M
YoY Change
Total Liabilities & Shareholders Equity $13.32M $14.07M $53.47M
YoY Change -68.49% -73.68% -50.83%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income $66.01M -$8.558M -$126.0M
YoY Change -26.26% -93.21% 276.89%
Depreciation, Depletion And Amortization $37.00K $173.0K $250.0K
YoY Change -85.2% -30.8% -7.41%
Cash From Operating Activities -$2.364M -$1.494M -$26.66M
YoY Change -85.5% -94.4% -50.24%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.000K -$170.0K
YoY Change -100.0% -100.59% -87.21%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$1.000K -$170.0K
YoY Change -100.0% -99.41% -87.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.138M 597.0K 41.36M
YoY Change -45.82% -98.56% -21.66%
NET CHANGE
Cash From Operating Activities -2.364M -1.494M -26.66M
Cash From Investing Activities 0.000 -1.000K -170.0K
Cash From Financing Activities 2.138M 597.0K 41.36M
Net Change In Cash -226.0K -898.0K 14.53M
YoY Change -98.18% -106.18% -791.11%
FREE CASH FLOW
Cash From Operating Activities -$2.364M -$1.494M -$26.66M
Capital Expenditures $0.00 $1.000K -$170.0K
Free Cash Flow -$2.364M -$1.495M -$26.49M
YoY Change -85.43% -94.36% -49.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001618835
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q2 EVFM Temporary Equity Convertible Preferred Stock Deemed Dividends
TemporaryEquityConvertiblePreferredStockDeemedDividends
usd
EVFM Temporary Equity Convertible Preferred Stock Deemed Dividends
TemporaryEquityConvertiblePreferredStockDeemedDividends
usd
CY2022Q1 EVFM Exchange Of Series B2 Convertible Preferred Stock Value
ExchangeOfSeriesB2ConvertiblePreferredStockValue
usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
usd
EVFM Financial Instrument Modification Expense
FinancialInstrumentModificationExpense
usd
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
EVFM Financial Instrument Expense Noncash
FinancialInstrumentExpenseNoncash
usd
EVFM Proceeds From Issuance Of Common Stock Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockStockPurchaseAgreement
usd
EVFM Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
EVFM Financing Costs Included In Accounts Payable And Accrued Expenses
FinancingCostsIncludedInAccountsPayableAndAccruedExpenses
usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
usd
EVFM Exchange Of Series B2 Convertible Preferred Stock To Series C Convertible Preferred Stock
ExchangeOfSeriesB2ConvertiblePreferredStockToSeriesCConvertiblePreferredStock
usd
us-gaap Stock Issued1
StockIssued1
usd
EVFM Issuance Of Common Stock Upon Exercise Of Purchase Rights
IssuanceOfCommonStockUponExerciseOfPurchaseRights
usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
usd
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36754
dei Entity Registrant Name
EntityRegistrantName
EVOFEM BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8527075
dei Entity Address Address Line1
EntityAddressAddressLine1
7770 Regents Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 113-618
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei City Area Code
CityAreaCode
(858)
dei Local Phone Number
LocalPhoneNumber
550-1900
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EVFM
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4060209 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2769000 usd
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
636000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1207000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5198000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1126000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
3674000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
5379000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2508000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2218000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
12016000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
12699000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1668000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3940000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
195000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4406000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
195000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4118000 usd
CY2023Q2 us-gaap Assets
Assets
14074000 usd
CY2022Q4 us-gaap Assets
Assets
25163000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
17151000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14984000 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
15600000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
39416000 usd
CY2023Q2 EVFM Convertible Notes Payable Current Adjuvant
ConvertibleNotesPayableCurrentAdjuvant
27401000 usd
CY2022Q4 EVFM Convertible Notes Payable Current Adjuvant
ConvertibleNotesPayableCurrentAdjuvant
26268000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4216000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4124000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1550000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2175000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
173000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2311000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1676000 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3625000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2876000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
69716000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
93830000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3133000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
69738000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
96963000 usd
CY2023Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2524239 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2524239 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
984786 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
984786 shares
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
820587000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
817367000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
73355000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
49527000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-949606000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-938694000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-55664000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-71800000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14074000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25163000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2458000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6034000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8267000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10285000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2293000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1285000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3669000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2351000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
402000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7744000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
942000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18135000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2197000 usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12298000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6051000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
25003000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4902000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9126000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8520000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18144000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
9794000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
30453000 usd
us-gaap Costs And Expenses
CostsAndExpenses
19182000 usd
us-gaap Costs And Expenses
CostsAndExpenses
63633000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7336000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24419000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10915000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-53348000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
26000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
5000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1127000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-415000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1445000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-886000 usd
CY2023Q2 EVFM Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
27000 usd
CY2022Q2 EVFM Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
71150000 usd
EVFM Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
111000 usd
EVFM Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
72002000 usd
CY2023Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-73000 usd
CY2022Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-29980000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
1539000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-31614000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1219000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-101541000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-104497000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8555000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-125960000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10906000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-157845000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8558000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-125980000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10912000 usd
us-gaap Net Income Loss
NetIncomeLoss
-157868000 usd
CY2022Q2 EVFM Temporary Equity Convertible Preferred Stock Deemed Dividends
TemporaryEquityConvertiblePreferredStockDeemedDividends
-1908000 usd
EVFM Temporary Equity Convertible Preferred Stock Deemed Dividends
TemporaryEquityConvertiblePreferredStockDeemedDividends
-1827000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8558000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-124072000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10912000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-156041000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.43
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.43
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-580.48
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-580.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-169.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-169.73
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.43
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.43
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-580.48
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-580.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-169.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-169.73
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1576158 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1576158 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
217028 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
217028 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1654026 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1654026 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
930112 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
930112 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1576158 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1576158 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
217028 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
217028 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1654026 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1654026 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
930112 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
930112 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8558000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-125980000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10912000 usd
us-gaap Net Income Loss
NetIncomeLoss
-157868000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
8368000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-3675000 usd
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
23828000 usd
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-3494000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-190000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129655000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12916000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-161362000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-71800000 usd
CY2023Q1 EVFM Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants
67000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1629000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
417000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
15460000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2354000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-56401000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-56401000 usd
CY2023Q2 EVFM Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants
101000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
53000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
499000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
268000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
8368000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8558000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-55664000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-55664000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-104315000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
5400000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
708000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
81000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
181000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
828000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1067000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31888000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-128100000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-128100000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
2553000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1264000 usd
CY2022Q2 EVFM Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants
32889000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
20000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
858000 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
18000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
543000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
543000 usd
CY2022Q2 EVFM Stock Issued During Period Value Exchange Transaction
StockIssuedDuringPeriodValueExchangeTransaction
2339000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-3675000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
231000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1081000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-125980000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-215995000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-215995000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10912000 usd
us-gaap Net Income Loss
NetIncomeLoss
-157868000 usd
EVFM Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
111000 usd
EVFM Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
72002000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
1539000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-31614000 usd
EVFM Financial Instrument Modification Expense
FinancialInstrumentModificationExpense
1056000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
685000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2148000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
418000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
515000 usd
us-gaap Interest Expense
InterestExpense
1134000 usd
us-gaap Interest Expense
InterestExpense
1055000 usd
us-gaap Lease Cost
LeaseCost
1208000 usd
us-gaap Lease Cost
LeaseCost
301000 usd
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
459000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1858000 usd
EVFM Financial Instrument Expense Noncash
FinancialInstrumentExpenseNoncash
514000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4072000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
855000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1705000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1542000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2435000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2749000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2167000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4728000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
840000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1929000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-625000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
816000 usd
EVFM Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1388000 usd
EVFM Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
469000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6434000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47579000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
236000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-236000 usd
EVFM Proceeds From Issuance Of Common Stock Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockStockPurchaseAgreement
7438000 usd
EVFM Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
24882000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
160000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
20922000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
20000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2138000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5892000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
859000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
18000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2298000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56493000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4140000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8678000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4776000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13588000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
636000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22266000 usd
EVFM Financing Costs Included In Accounts Payable And Accrued Expenses
FinancingCostsIncludedInAccountsPayableAndAccruedExpenses
563000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
189000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1187000 usd
EVFM Exchange Of Series B2 Convertible Preferred Stock To Series C Convertible Preferred Stock
ExchangeOfSeriesB2ConvertiblePreferredStockToSeriesCConvertiblePreferredStock
1616000 usd
us-gaap Stock Issued1
StockIssued1
858000 usd
EVFM Issuance Of Common Stock Upon Exercise Of Purchase Rights
IssuanceOfCommonStockUponExerciseOfPurchaseRights
186000 usd
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
a reverse stock split between 1-for-20 and not more than 1-for-125 at any time on or prior to March 15, 2024. The Company determined on a ratio of 1-for-125 for the Reverse Stock Split. On May 18, 2023, the Reverse Stock Split became effective.
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2100000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
600000 usd
CY2023Q2 EVFM Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
57700000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-949600000 usd
CY2022Q4 us-gaap Share Price
SharePrice
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
EVFM Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
100000000.0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_z1980Py7mhNc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zqIBgZki02D8">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the discount rate used in estimating the fair value of the lease right<b>-</b>of<b>-</b>use (ROU) assets and lease liabilities; the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued; the useful lives of property and equipment; the recoverability of long-lived assets; clinical trial accruals; the assumptions used in estimating the fair value of stock-based compensation expense. These assumptions are more fully described in <span style="text-decoration: underline">Note 3 – Revenue</span>, <span style="text-decoration: underline">Note 4 – Debt</span>, <span style="text-decoration: underline">Note 6 – Fair Value of Financial Instruments</span>, <span style="text-decoration: underline">Note 7 – Commitments and Contingencies</span> and <span style="text-decoration: underline">Note 9 – Stock-based Compensation</span>. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4142000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1388000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 integer
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zhSA6f7SXxf8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zik1mXMSKCPl">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by the Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company’s deposits were primarily held in Silicon Valley Bank prior to its closure by regulators, however, the Company was able to regain full access to all its deposits and subsequently moved these to a different financial institution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers and its past collection experience. Historically, the Company has not experienced any credit losses. As of June 30, 2023 and December 31, 2022, based on the evaluation of these factors, the Company did not record an allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phexxi is distributed primarily through three major distributors and a mail-order pharmacy, which receive service fees calculated as a percentage of the gross sales, and fee per units shipped, respectively. These entities are not obligated to purchase any set number of units and distribute Phexxi on demand as orders are received. For the three and six months ended June 30, 2023, the Company’s three largest customers combined made up approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUHwzDDV65pf" title="Concentration risk percent">81</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGiEzLvv8b78" title="Concentration risk percent">84</span>% of its gross product sales, respectively. For the three and six months ended June 30, 2022, the Company’s three largest customers combined made up approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXviOFgHom05" title="Concentration risk percent">72</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwbH2TxX5GVb" title="Concentration risk percent">71</span>% of its gross product sales, respectively. As of June 30, 2023 and December 31, 2022, the Company’s three largest customers combined made up <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zu1RlmXZGg6" title="Concentration risk percent">90</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVSzKxzaoisa" title="Concentration risk percent">81</span>%, respectively, of its trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Significant Accounting Policies</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no changes to the significant accounting policies that were described in <span style="text-decoration: underline">Note 2 – Summary of Significant Accounting Policies</span> of the 2022 Audited Financial Statements in the Company’s Annual Report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
25000000.0 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19885000 usd
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
636000 usd
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
1581000 usd
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
800000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
636000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22266000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
191005656 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1003965 shares
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1748000 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
3833000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
6648000 usd
CY2022Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
200000 usd
CY2021Q4 EVFM Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities
PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities
50000000 usd
EVFM Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
100000000.0 usd
CY2023Q1 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
92700000 usd
CY2023Q1 us-gaap Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
3 integer
EVFM Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
100000000.0 usd
CY2023Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
507000 usd
CY2022Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
523000 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1004000 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1035000 usd
CY2023Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
60000 usd
CY2022Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
10000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
128000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
19000 usd
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
567000 usd
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
533000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1132000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1054000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 EVFM Purchase Agreement Proceeds From Sale Of Equity Securities
PurchaseAgreementProceedsFromSaleOfEquitySecurities
900000 usd
CY2023Q1 EVFM Purchase Agreement Proceeds From Sale Of Equity Securities
PurchaseAgreementProceedsFromSaleOfEquitySecurities
400000 usd
CY2023Q1 EVFM Purchase Agreement Proceeds From Sale Of Equity Securities
PurchaseAgreementProceedsFromSaleOfEquitySecurities
300000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
740000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
758000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1705000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1300000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2508000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2218000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2863000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7129000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1195000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3189000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1668000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3940000 usd
CY2023Q2 EVFM Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
2498000 usd
CY2022Q4 EVFM Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
2574000 usd
CY2023Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
920000 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
674000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
798000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
876000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4216000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4124000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2612000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
303000 usd
EVFM Number Of Leased Vehicles
NumberOfLeasedVehicles
21 integer
CY2019Q4 EVFM Office Square Footage
OfficeSquareFootage
24474 sqft
CY2019Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q2 EVFM Office Square Footage
OfficeSquareFootage
8816 sqft
CY2022Q2 EVFM Lessee Operating Sublease Rentable Area
LesseeOperatingSubleaseRentableArea
16637 sqft
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
CY2022Q2 us-gaap Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate
OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate
0.035 pure
us-gaap Sublease Income
SubleaseIncome
300000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
250000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
603000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
706000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1179000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M1D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M4D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
94000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
109000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
212000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
195000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
268000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1081000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
685000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2148000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1427000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1289000 usd
CY2023Q2 us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
0 usd
us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
0 usd
CY2022Q2 us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
0 usd
us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
0 usd
CY2023Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1300000 usd
CY2023Q2 EVFM Accounts Payable Trade90 Days Past Due Or More Percent
AccountsPayableTrade90DaysPastDueOrMorePercent
0.98 pure
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3642343 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 EVFM Common Stock Reserved Upon Exercise Of Common Stock Warrants
CommonStockReservedUponExerciseOfCommonStockWarrants
3642343000 shares
CY2023Q2 EVFM Common Stock Capital Share Reserved For Future Issuance
CommonStockCapitalShareReservedForFutureIssuance
28783233000 shares
CY2023Q2 EVFM Common Stock Reserved For Conversion Of Convertible Notes
CommonStockReservedForConversionOfConvertibleNotes
158575812000 shares
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
191012042000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares

Files In Submission

Name View Source Status
0001493152-23-028671-index-headers.html Edgar Link pending
0001493152-23-028671-index.html Edgar Link pending
0001493152-23-028671.txt Edgar Link pending
0001493152-23-028671-xbrl.zip Edgar Link pending
evfm-20230630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
evfm-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
evfm-20230630_lab.xml Edgar Link unprocessable
evfm-20230630_def.xml Edgar Link unprocessable
evfm-20230630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending